ACRO Biomedical Co., Ltd. (TWO:6748) — Market Cap & Net Worth
Market Cap & Net Worth: ACRO Biomedical Co., Ltd. (6748)
ACRO Biomedical Co., Ltd. (TWO:6748) has a market capitalization of $150.33 Million (NT$4.77 Billion) as of April 17, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #19120 globally and #985 in its home market, demonstrating a -0.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACRO Biomedical Co., Ltd.'s stock price NT$67.00 by its total outstanding shares 71218000 (71.22 Million).
ACRO Biomedical Co., Ltd. Market Cap History: 2026 to 2026
ACRO Biomedical Co., Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $150.33 Million to $150.33 Million (0.00% CAGR).
ACRO Biomedical Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACRO Biomedical Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6748 by Market Capitalization
Companies near ACRO Biomedical Co., Ltd. in the global market cap rankings as of April 17, 2026.
Key companies related to ACRO Biomedical Co., Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $110.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #292 globally with a market cap of $77.51 Billion USD.
- UCB SA (BR:UCB): Ranked #448 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #462 globally with a market cap of $50.32 Billion USD ( R$256.46 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.53 Billion | $435.65 |
| #292 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.51 Billion | $746.00 |
| #448 | UCB SA | BR:UCB | $51.74 Billion | €258.70 |
| #462 | argenx SE | SA:A1RG34 | $50.32 Billion | R$164.96 |
ACRO Biomedical Co., Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, ACRO Biomedical Co., Ltd.'s market cap moved from $150.33 Million to $ 150.33 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$150.33 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 17th, 2026 the market cap of ACRO Biomedical Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $150.33 Million USD |
| MoneyControl | $150.33 Million USD |
| MarketWatch | $150.33 Million USD |
| marketcap.company | $150.33 Million USD |
| Reuters | $150.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.